Company: ENTXW
Filing Date: 2025-05-14
Form Type: PRE 14A
Source: 0001178913-25-001794
Chunk: 60

Company: Entera Bio Ltd.
Filing Date: 2025-05-14
Form: PRE 14A
Chunk 60
---
2025 comparative executive compensation benchmark analyses, which included comparative data of the Company’s executive compensation relative to the peer-group companies in Israel and in the United States. Our Compensation Committee and Board believe that it is in the best interest of the Company and our shareholders to approve the one-time grant of compensation and salary increase to Ms. Toledano, our Chief Executive Officer. 36 The terms of the compensation to Ms. Toledano, effective as of the approval of our shareholders at this Annual Meeting, would be as follows:

| (i) | 2025 Option Grant. Ms. Toledano will be entitled to receive an additional one-time grant of options to purchase an additional 500,000 Ordinary Shares (the “2025 Options”), at an exercise price of $2.28 per Ordinary Share, under the 2018 Plan, and subject to the requirements of applicable laws and regulations. The 2025 Options shall vest as follows: provided that Ms. Toledano has not undergone a Termination of Service (as defined in the 2018 Plan) prior to the applicable vesting date, the 2025 Options shall vest over a three (3) year period, with a third of the 2025 Options vesting at the end of a 12-month period following April 28, 2025 and the remaining two-thirds of the 2025 Options shall vest in eight substantially equal portions over the next two (2) year period thereafter, on a quarterly basis, rounded down to the nearest whole share, provided, that with respect to the last such quarterly installment, the number of 2025 Options that vest in the installment shall be such that Ms. Toledano will be fully vested in the total number of 2025 Options listed above as of such applicable quarterly anniversary (i.e., such that one hundred percent (100%) of the 2025 Options shall become fully vested on April 28, 2028); provided further, however, that in the event of a Change in Control (as defined in the 2018 Plan) in which Ms. Toledano continues to provide services to the Company on the date of consummation of such Change in Control, 100% of any unvested 2025 Options at the time of the consummation of such Change in Control shall become fully vested and exercisable. The expiration date of the 2025 Options shall be April 28, 2035, or such earlier date in accordance with the 2018 Plan or